Interestingly, we found a significant increase of cGAS (p < 0.01), IL-1β (p < 0.01) and CCL5 (p < 0.05) in NSCLC patients-derived PBMCs after treatment with MET compared to untreated CTR. This evidence concerns the gene IL1B and non-small cell lung carcinoma.